News

We Are Excited to Announce Filtricine's Latest Round of Investment

August 3, 2021

We are excited to announce Filtricine's latest round of investment led by Boutique Venture Partners and Berkeley Catalyst Fund with the continuing participation of True Ventures, SOSV, Sand Hill Angels and Bluestein Ventures. Proceeds will be used to support our ongoing prostate cancer trial at Stanford University School of Medicine along with additional trials.Our prostate cancer clinical trial continues to recruit patients.

https://clinicaltrials.gov/ct2/show/NCT04389918

Latest News

Filtricine Preclinical Results Published

December 22, 2021
Filtricine is pleased to announce that the preclinical research results of its proprietary medical food technology
Read more

Clinical Results Presented at PCF Retreat

November 6, 2021
Filtricine is pleased to announce that researchers leading a Filtricine-sponsored prostate cancer clinical study at Stanford University
Read more

Filtricine Appoints a New Chief Executive Officer

December 22, 2020
It is our great pleasure to announce that Dr. John Chant has accepted our offer as Chief Executive Officer.
Read more

Filtricine Initiates the First Clinical Study

July 8, 2020
Filtricine today announced the start of its first human clinical study among prostate cancer patients.
Read more

Filtricine Presents Research at Scientific Conference for Cancer Treatment

November 1, 2019
At the AACR-NCI-EORTC conference for molecular targets (#Targets19) in Boston
Read more

IndieBio Demo Day Presentation

November 6, 2018
We proudly graduated from the phenomenal four-month program at IndieBio.
Read more
View all
We are a clinical-stage biotechnology company based in the San Francisco Bay Area dedicated to developing novel food products for disease control.
© 2022 Filtricine, Inc. All Rights Reserved | by Wuilt
Privacy PolicyTerms of use